Allergan’s Viberzi shows effectiveness against irritable bowel syndrome

Allergan has announced the findings of a pair of clinical trials that demonstrate the effectiveness of its irritable bowel syndrome therapy Viberzi.

A prespecified prospective pooled subgroup analysis from two phase III studies has demonstrated the efficacy and safety of Viberzi in nearly 2,500 patients with irritable bowel syndrome with diarrhoea and abdominal pain.

It was shown that Viberzi was able to safely and effectively treats symptoms of abdominal pain and diarrhea irrespective of prior use of loperamide, while also demonstrating efficacy in those using loperamide rescue medication.

Viberzi offers mixed opioid receptor modulator activity, acting as a mu and kappa-opioid receptor agonist and a delta-opioid receptor antagonist. It works locally in the gut and has been shown to decrease visceral hypersensitivity and control gastrointestinal motility.

Dr David Nicholson, chief research and development officer of Allergan, said: "These results continue to build on the robust clinical profile that has already been established, and further underscores Viberzi as a safe and effective treatment option."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.